---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-22-000034"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:40:58.797987+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Recursion reports Q3 net loss of $60.4M, initiates two clinical trials; raises $150M private placement

## Summary
- Cash and cash equivalents $454.6M as of Sept 30, 2022; excludes $150.3M private placement closed Oct 27.
- Revenue $13.2M (up from $2.5M YoY) on Roche-Genentech collaboration; net loss $60.4M vs $47.4M YoY.
- Initiated Phase 2 TUPELO trial for REC-4881 in FAP and Phase 1 trial for REC-3964 in C. diff colitis.
- Nominated REC-4881 for AXIN1/APC mutant cancers; planning Phase 2 trial; deprioritized GM2 gangliosidosis.
- R&D expenses $40.8M, G&A $19.5M; both increased due to clinical progress and company growth.

## SEC filing metadata
- accession: 0001601830-22-000034
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183022000034/0001601830-22-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183022000034/rxrx-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-22-000034
- JSON: https://secwatch.observer/filing/0001601830-22-000034.json
- Plain text: https://secwatch.observer/filing/0001601830-22-000034.txt

## Key facts
- Earnings Releases
  RECURSION PHARMACEUTICALS, INC. reported third quarter September 30, 2022 results: revenue 13.2 million.
  - Period: third quarter September 30, 2022
  - Revenue: 13.2 million
  - Result: reported results
  source text: Total revenue, consisting primarily of revenue from collaborative agreements, was $13.2 million for the third quarter of 2022, compared to $2.5 million for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183022000034/0001601830-22-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.